CSIMarket
 


Genetic Technologies Limited  (GENE)
Other Ticker:  
 

Genetic Technologies Limited's Leverage Ratio

GENE's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to repayements of liabilities of 0% Genetic Technologies Limited improved Leverage Ratio in third quarter 2019 to 0.84, a new company high.

Within Biotechnology & Pharmaceuticals industry in the third quarter 2019, 182 other companies have achieved lower Leverage Ratio than Genetic Technologies Limited in the III Quarter 2019. While Leverage Ratio total ranking has improved so far in the third quarter 2019 to 2113, from total ranking in the second quarter 2019 at 2167 .

Explain Leverage Ratio?
Who are GENE Customers?
What are GENE´s Total Liabilities?


GENE Leverage Ratio 0
III. Quarter
0
II. Quarter
0
I. Quarter
(Jun 30 2018)
IV. Quarter
0
III. Quarter
Y / Y Equity Change -62.41 % -62.41 % -62.41 % - -
Y / Y Total Liabilities Change 2.73 % 2.73 % 2.73 % - -
Leverage Ratio MRQ 0.84 0.84 0.84 0.31 0.31
GENE's Total Ranking # 2113 # 2167 # 2167 # 1032 # 806
Seq. Equity Change 0 % 0 % -62.41 % 0 % 0 %
Seq. Total Liabilities Change 0 % 0 % 2.73 % 0 % 0 %



Leverage Ratio third quarter 2019 Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 183
Healthcare Sector # 738
Overall Market # 2113


Leverage Ratio Statistics
High Average Low
0.84 0.58 0.31
(Jun 30 2019)   (Jun 30 2018)




Financial Statements
Genetic Technologies Limited's Equity $ 2 Millions Visit GENE's Balance sheet
Genetic Technologies Limited's Total Liabilities $ 1 Millions Visit GENE's Balance sheet
Source of GENE's Sales Visit GENE's Sales by Geography


Cumulative Genetic Technologies Limited's Leverage Ratio

GENE's Leverage Ratio for the trailling 12 Months

GENE Leverage Ratio

0
III. Quarter
0
II. Quarter
0
I. Quarter
(Jun 30 2018)
IV. Quarter
0
III. Quarter
Y / Y Equity TTM Growth -62.41 % -62.41 % -62.41 % - -
Y / Y Total Liabilities TTM Growth 2.73 % 2.73 % 2.73 % - -
Leverage Ratio TTM 0.59 0.45 0.37 0.31 0.31
Total Ranking TTM # 16 # 16 # 0 # 0 # 0
Seq. Equity TTM Growth 0 % 0 % -62.41 % 0 % 0 %
Seq. Total Liabilities TTM Growth 0 % 0 % 2.73 % 0 % 0 %


On the trailing twelve months basis Despite of the repayements of liabilities of 0% in the trailing twelve months ending in III Quarter 2019, Leverage Ratio improved to 0.59, above Genetic Technologies Limited's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Biotechnology & Pharmaceuticals industry GENE recorded the lowest Leverage Ratio. While total ranking remained unchanged compared to previous 12 month period at no. 16.

Explain Leverage Ratio?
Who are GENE Customers?
What are GENE´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Biotechnology & Pharmaceuticals Industry # 0
Healthcare Sector # 0
Within the Market # 16


trailing twelve months Leverage Ratio Statistics
High Average Low
0.84 0.58 0.31
(Jun 30 2019)   (Jun 30 2018)




Companies with similar Leverage Ratio in the quarter ending 0, within Biotechnology & Pharmaceuticals Industry Leverage Ratio0 MRQ Total Liabilities0 MRQ Equity
Vaxart Inc   1.89 $ 23.733  Millions$ 12.576  Millions
La Jolla Pharmaceutical Company  1.86 $ 21.033  Millions$ 11.301  Millions
Gilead Sciences Inc   1.67 $ 36,912.000  Millions$ 22,091.000  Millions
Neurocrine Biosciences Inc   1.34 $ 548.448  Millions$ 409.275  Millions
Nanostring Technologies Inc   1.30 $ 122.730  Millions$ 94.600  Millions
Jounce Therapeutics inc   1.26 $ 118.785  Millions$ 94.424  Millions
Acorda Therapeutics Inc   1.18 $ 667.352  Millions$ 566.586  Millions
Pluri Inc   1.17 $ 10.104  Millions$ 8.627  Millions
X4 Pharmaceuticals Inc  1.12 $ 33.108  Millions$ 29.441  Millions
Aevi Genomic Medicine, Inc.  1.05 $ 3.892  Millions$ 3.721  Millions
Qiagen N v   1.01 $ 2,569.382  Millions$ 2,536.591  Millions
Armata Pharmaceuticals Inc   0.94 $ 4.656  Millions$ 4.961  Millions
Biogen Inc   0.91 $ 12,615.600  Millions$ 13,822.000  Millions
Alector Inc   0.86 $ 229.858  Millions$ 266.186  Millions
Innate Pharma Sa  0.85 $ 206.018  Millions$ 243.506  Millions
Genetic Technologies Limited  0.84 $ 1.494  Millions$ 1.771  Millions
Eiger Biopharmaceuticals Inc   0.79 $ 40.230  Millions$ 50.808  Millions
Meiragtx Holdings Plc  0.79 $ 113.436  Millions$ 144.418  Millions
Windtree Therapeutics Inc  0.77 $ 48.630  Millions$ 62.996  Millions
Editas Medicine Inc   0.74 $ 161.754  Millions$ 217.162  Millions
Surface Oncology Inc   0.70 $ 70.215  Millions$ 100.393  Millions
Atyr Pharma Inc   0.69 $ 20.430  Millions$ 29.485  Millions
Spark Therapeutics Inc   0.68 $ 304.480  Millions$ 451.028  Millions
Eloxx Pharmaceuticals Inc   0.65 $ 22.458  Millions$ 34.433  Millions
Sangamo Therapeutics Inc   0.65 $ 214.234  Millions$ 329.181  Millions
Halozyme Therapeutics Inc   0.63 $ 164.815  Millions$ 260.047  Millions
Bio techne Corp  0.62 $ 716.240  Millions$ 1,146.266  Millions
Biontech Se  0.62 $ 340.654  Millions$ 552.711  Millions
Tracon Pharmaceuticals Inc   0.56 $ 8.348  Millions$ 14.805  Millions
Sutro Biopharma Inc   0.55 $ 71.740  Millions$ 130.718  Millions

Date modified: -0001-11-30T00:00:00+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com